NasdaqGM:EYPTPharmaceuticals
EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact
EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock.
See our latest analysis for EyePoint.
The LUGANO readout has sharply reset expectations around EyePoint, with the share price down about 73% year to date and the 1 year total shareholder return declining about 57%. This points to fading momentum as investors reassess both execution risk and future...